Recent work from our lab has demonstrated that Entinostat (a Class I-specific HDAC inhibitor) can suppress p53-induced FLIPL upregulation in response to treatment with Nutlin-3A and chemotherapeutic agents in models of colorectal cancer [75]. This evidence concerns the gene HDAC9 and colorectal cancer.